Diametric Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Diametric Capital’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$276K	Buy	+10,531	New	+$245K	0.03%	405
2025 Q4	–	Sell	-31,477	Closed	-$593K	–	384
2025 Q3	$593K	Sell	31,477 -7,381	-19%	-$116K	0.22%	114
2025 Q2	$545K	Buy	38,858 +14,514	+60%	+$203K	0.29%	98
2025 Q1	$381K	Buy	24,344 +3,974	+20%	+$56K	0.45%	77
2024 Q4	$284K	Sell	20,370 -12,537	-38%	-$137K	0.19%	168
2024 Q3	$306K	Buy	32,907 +20,481	+165%	+$202K	0.15%	208
2024 Q2	$116K	Buy	+12,426	New	+$112K	0.06%	302
2023 Q2	–	Sell	-14,644	Closed	-$161K	–	353
2023 Q1	$161K	Buy	+14,644	New	+$212K	0.08%	240

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Diametric Capital's ARQT Position: Q2 2026 in Review

Diametric Capital opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 10,531 shares worth $276K. The stake represents 0.03% of the portfolio and ranks #405 among its holdings. This is a return to the name: Diametric Capital previously reported a position in ARQT as recently as Q3 2025.

Diametric Capital first reported a position in ARQT in Q1 2023 and has held it in 8 quarters since. The position peaked at $593K in Q3 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Diametric Capital held 10,531 shares of Arcutis Biotherapeutics worth $276K as of Q2 2026.
Arcutis Biotherapeutics was a new Diametric Capital position in Q2 2026.
Arcutis Biotherapeutics made up 0.03% of Diametric Capital's portfolio in Q2 2026, its #405 holding.
Diametric Capital first reported a position in Arcutis Biotherapeutics in Q1 2023 and has held it in 8 quarters since.
Diametric Capital's Arcutis Biotherapeutics position peaked at $593K in Q3 2025.
273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.